ACR is the premier Rheumatology meeting, so the fact we get to present the DMOAD results is validation of the DMOAD results, otherwise the poster would've been knocked back. It's surprisingly difficult to get a slot at ACR and these posters go through a detailed selection process. In addition, this is the meeting where the best Rheumatologists from all around the world converge, so we should get some good attention. The only other thing I would add is the ACR is a great opportunity to collaborate, so hopefully Ravi and Mukesh keep this in mind when they attend. How do I know all this? Because I attended the 2018 one in Chicago where nearly 20,000 people were in attendence.
ACR is the premier Rheumatology meeting, so the fact we get to...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $116.0K | 491.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 33682 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |